公开(公告)号：US20230201231A1

公开(公告)日：2023-06-29

申请号：US18087345

申请日：2022-12-22

Applicant: AMGEN INC. ,  Atara Biotherapeutics, Inc.

Inventor： Huiquan HAN ,  Christopher Michael HAQQ ,  Isaac CIECHANOVER ,  Xiaolan ZHOU ,  John Zhao-Nian LU

IPC: A61K31/704 ,  A61K45/06 ,  A61K31/7068 ,  C07K16/22 ,  A61K38/17 ,  A61K39/395

CPC classification number: A61K31/704 ,  A61K45/06 ,  A61K31/7068 ,  C07K16/22 ,  A61K38/177 ,  A61K39/3955 ,  A61K39/39558 ,  A61K38/1796 ,  A61K2039/505

Abstract: The present invention relates to methods of treating ovarian cancer in a subject by administering to the subject by evaluating the subject's expression levels of specific biomarkers or angiogenic an anti-activin-A compound, such as an anti-activin-A antibody or an activin-A-binding receptor. In some embodiments, at least two compounds are administered to the subject, where the first compound is an anti-activin A compound, and the second compound is a chemotherapeutic compound, for example capecitabine. The invention further relates to methods of identifying subjects for treatment factors.